Agentix Corp. Liquidation Value

AGTX Biotechnology

Cash & Equivalents

$6,396
As of 2025-12-31
Current Price: $0.04 (as of 2026-05-10)

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $6,396
Total Obligations: -$3.50M
$-3.50M
Per share: $-0.09
Period: 2025-12-31
incomplete 3 components missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)
  • Finance Lease Liability: not reported
  • Operating Lease Liability: not reported

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $6,396
AR: N/A
Total Obligations: -$3.50M
$-3.50M
Per share: $-0.09
Period: 2025-12-31
incomplete 4 components missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)
  • Accounts Receivable: not reported
  • Finance Lease Liability: not reported
  • Operating Lease Liability: not reported

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $6,396
AR: N/A
Inventory: N/A
Total Obligations: -$3.50M
$-3.50M
Per share: $-0.09
Period: 2025-12-31
incomplete 5 components missing — treated as $0 in formula. Why?
  • Inventory: not reported in this period (annual-only)
  • Long-Term Debt: not reported in this period (annual-only)
  • Accounts Receivable: not reported
  • Finance Lease Liability: not reported
  • Operating Lease Liability: not reported

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$-3.50M$-0.09
Liquid Liquidation Value$-3.50M$-0.09
Operating Liquidation Value$-3.50M$-0.09

Key Components (as of 2025-12-31)

Note: Financial institutions (banks, REITs, insurance companies) use specialized accounting standards that differ from standard GAAP balance sheet presentation. Liquidation metrics may not apply and are shown as N/A where data is unavailable. See our methodology page for details.

Data as of 2025-12-31 from 10-Q filed 2026-02-17. View on SEC EDGAR →

Cash & Equivalents$6,396
Accounts ReceivableN/A
InventoryN/A
Current Liabilities$3.50M
Long-term DebtN/A
Op. Lease LiabilityN/A
Finance LeaseN/A
Shares Outstanding40.1M

Explore all 48 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2025-12-31$6,396N/AN/A$707,215$3.50MN/AN/AN/A
2025-09-30$5,601N/AN/A$711,639$3.42MN/AN/AN/A
2025-06-30$4,412N/AN/A$700,149$3.28MN/AN/AN/A
2025-03-31$4,477N/AN/A$968,888$3.20MN/AN/AN/A

Comments

SEC Filings

PeriodFormFiledLink
2025-12-31 10-Q 2026-02-17 View
2025-09-30 10-Q 2025-11-20 View
2025-06-30 10-Q 2025-08-22 View
2025-03-31 10-K 2025-07-16 View
2024-12-31 10-Q 2025-02-18 View
2024-09-30 10-Q 2024-11-18 View
2024-06-30 10-Q 2024-09-25 View
2024-03-31 10-K 2024-08-30 View

AI Insights

AI Insight·Generated 2026-05-06

Agentix Corp. (AGTX) is a clinical-stage biotechnology company with zero revenue, zero productive assets, and a balance sheet that is entirely insolvent under any liquidation framework. As of December 31, 2025, total assets equal $6,396 — the entirety of which is cash. Under the liquidation lens, cash recovers at 100%, yielding gross recoverable assets of $6,396. Total liabilities at face value are $3,504,396, all current, resulting in a liquidation value to equity of approximately negative $3.50 million. This matches the reported MFFAIS CLV/LLV/OLV of -$3,498,000 exactly, as the sole asset is cash and the sole liability stack is current payables and notes. There are no PP&E, no inventory, no intangibles, and no long-term liabilities to haircut or unwind. The deficit position worsened from the prior period (September 30, 2025 stockholders' deficit of -$3,418,038) by approximately $80,000, driven by the Q3 net loss of $78,595. The liability stack is dominated by related-party accounts payable of $2,320,221 (owed to SBS Management LLC at $1,431k, Gray's Peak Capital at $518k, and management/board at $433k), a related-party secured note payable to Gray's Peak Private Credit LLC of $353,450 (bearing 2% per month interest after 30 days, extended to June 30, 2026, secured by all company assets), and third-party accounts payable of $707,215. Accrued interest on the Gray's Peak note of $121,322 is included in the $123,510 accrued liabilities balance. Critically, the Gray's Peak note is secured by a first-priority pledge over all company assets, placing it senior to all other creditors and equity in any wind-down. The prepaid clinical research balance of $95,797 that existed at March 31, 2025 has been fully consumed, leaving no prepaid assets. The filing carries a going concern qualification. No deferred revenue, no operating leases, no pension obligations, and no off-balance-sheet commitments are disclosed. The only financing activity YTD is $110,450 in new proceeds from debt issuance (additional draws on the Gray's Peak facility), which has funded operating cash burn of $123,305 for the nine months ended December 31, 2025. Filing discusses the Gray's Peak note's secured status and 2% per month interest in the notes but does not separately XBRL-tag the collateral pledge or effective annualized interest rate.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...